This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Johnson & Johnson vs. Goldman & Goldman: Street Whispers

NEW YORK ( TheStreet) -- In Goldman Sachs' (GS - Get Report) Tuesday downgrade of Johnson & Johnson (JNJ - Get Report) to 'Sell,' Wall Street watchers might want to chalk up a win for reform... and bankers' love of advisory fees.

The Goldman research arm's bearish outlook on J&J -- predicated on a misguided M&A strategy -- comes months after Goldman's investment bankers helped seal the healthcare giant's largest-ever acquisition.

On the face of it, there's nothing surprising about Goldman's downgrade of J&J. After all, the company has significantly underperformed the Dow Jones U.S. Pharmaceuticals Index ( DJUSPR) in the past year and it faces an onslaught of competition from the likes of Pfizer (PFE - Get Report), Abbot Laboratories (ABT), Covidien (COV) and Baxter International (BAX), who are in the process of spinning off non-pharma businesses, giving investors a choice of pure-play drug makers that may be industry aggressors in coming quarters.

The real surprise is how arguments floated by Goldman's research analysts appear to undercut the bank's front and center role as an adviser to J&J on its $19.7 billion acquisition of medical device maker Synthes, the largest deal in the company's 126-year history. The downgrade is especially noteworthy given that Goldman's advisory work for J&J was also likely considered to be a capstone 2012 success in a relatively weak year for dealmakers.

In April 2011, Goldman was the sole advisor to the Synthes acquisition, initially a cash and stock deal that was forecast by management to be dilutive to J&J's earnings per share. However, in June of this year, Goldman and JPMorgan (JPM - Get Report) structured a complicated share swap where J&J could effectively use cash abroad instead of a secondary stock offering in the U.S. to finance the merger, magically turning what was a dilutive acquisition into an EPS accretive M&A overnight.

In fact, the deal, which exploited a loophole on how the Internal Revenue Service taxes foreign earnings, propelled the IRS to plug the hole shortly thereafter, according to a July 23 interview with tax expert Robert Willens. Talk about bankers adding value.

Give credit to Goldman for uncovering financial maneuvers to turn the Synthes acquisition from a 5 cent EPS drag on J&J's forecast 2013 earnings to a 15 cent benefit.

Other parts of the bank didn't seem to take notice, even if the swap radically changed perceptions on the deal, giving Jefferies and JPMorgan analysts reason to upgrade their outlook on J&J's shares.

In late May, as J&J was seeking European Commission antitrust approvals for its Synthes acquisition, Goldman Sachs research analyst Jami Rubin argued that the company's M&A ambition and its doubling down on a conglomerate corporate structure would backfire relative to the competition.

On Tuesday, Rubin underscored the argument, downgrading J&J to a 'Sell,' citing the company's M&A strategy and competitive threats to its drugs unit. "[JNJ's] focus on M&A versus cash returns to shareholders or a break-up strategy (like PFE, ABT, COV, BAX) puts it at a disadvantage as other companies get more aggressive," writes Rubin in the report, which argues J&J's stock is worth just $72, far below other estimates. In early afternoon trading, J&J's shares were off nearly 2% to $68.26.

Rubin goes on to argue that a focus on drug R&D pipelines and shareholder friendly management of corporate purse strings are the biggest catalysts to the pharma sector as a whole, and recommends companies like Pfizer, Abbott Labs, Covidien and Baxter International over J&J.

In March, Rubin floated the idea that Pfizer should consider breaking up to a bigger degree than management's plan to divest non-drugs assets like its animal health and baby nutrition units, signaling conviction behind the benefits of pure play pharma businesses over conglomerates.

The differing perspectives on J&J offered by Goldman by way of its investment bankers as an adviser to the company and its research analysts as an independent monitor on the company's share performance appear to add a new twist to the perception Wall Street research is compromised by the drive for lucrative M&A and IPO-related fees.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
GS $206.35 -0.24%
JPM $68.77 -0.25%
JNJ $99.50 -0.23%
PFE $35.61 -0.42%
AAPL $122.06 -0.76%

Markets

Chart of I:DJI
DOW 17,693.90 -57.49 -0.32%
S&P 500 2,099.84 -8.73 -0.41%
NASDAQ 5,089.5870 -22.1460 -0.43%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs